LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07143110

Acronym

LUNG-ROLL

Enrollment

60000

Registered

2025-08-27

Start date

2025-08-20

Completion date

2027-09-30

Last updated

2026-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Neoplasms

Keywords

Lung Neoplasms, Non-Small-Cell Lung, Small Cell Lung, Epidemiology, Treatment Patterns, Real-World

Brief summary

LUNG-ROLL is a retrospective cohort study that will describe the contemporary treatment patterns, prevalence and incidence, patient demographic and clinical characteristics, clinical outcomes, and healthcare resource use/costs for patients with lung cancer in Canada (specifically, Alberta and Ontario) using administrative data.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 130 Years

Healthy volunteers

Inclusion criteria

* Patients with lung cancer between January 1, 2018 and end of the Selection Period. * Patient is 18 years of age or older on diagnosis date. * Patient has at least 12 months of health insurance coverage prior to the diagnosis date.

Exclusion criteria

* Diagnosed with any other cancer in the 5-year period prior to January 1, 2018. * Diagnosed with any other cancer concurrently (i.e., on the same date) as lung cancer diagnosis. * Invalid or incomplete records for key variables (e.g., missing year of diagnosis, missing cancer type). * Non-Ontario or non-Alberta resident on diagnosis date.

Design outcomes

Primary

Measure	Time frame
Treatment patterns	Through study completion, an average of 1 year

Secondary

Measure	Time frame
Incidence and prevalence	Through study completion, an average of 1 year
Baseline demographic and clinical characteristics	Through study completion, an average of 1 year
Overall survival	Through study completion, an average of 6 months
Time to/on therapy	Through study completion, an average of 6 months
Attrition rates	Through study completion, an average of 1 year
Healthcare resource utilization (HCRU)	Through study completion, an average of 1 year
Direct healthcare costs	Through study completion, an average of 1 year

Countries

Canada

Contacts

CONTACTAstraZeneca Clinical Study Information Center

information.center@astrazeneca.com1-877-240-9479

Outcome results